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1. Introduction 
Quietly, cautiously, and steadily, the field of modern medicine recently progressed across a 
new threshold with the development of Rexin-G, the first and so far, only, targeted 
injectable molecular genetic medicine to be validated in the clinic. Designed to function 
within the context and complexities of the human circulatory system, the “smart,” “stealth,” 
“highly-selective” nanoparticles embodied in Rexin-G travel beyond the reach of the most 
gifted surgeons, beyond the horizons of the finest catheters, to seek out the biochemical 
hallmarks of invasive cancers, and to deliver a lethal genetic payload where it is needed 
most—i.e., targeting the histopathology of the tumor microenvironment. In this invited 
review, we elaborate upon the critical stages of scientific discovery, molecular-genetic target 
validation, preclinical studies, pathotropic (disease-seeking) platform development, clinical 
trial design, molecular pharmacology, regulatory considerations, and GMP production & 
bioprocessing that, taken together, define the advancement of this tumor-targeted genetic 
medicine for cancer. In the course of delineating the developmental trajectory of Rexin-G 
into a series of logical and discrete stages, the authors have endeavored to extract, abstract, 
and represent a host of molecular biotechnological innovations in an accessible manner, 
providing (i) a useful overview of the converging fields of applied genetics, nanotechnology, 
and molecular biotechnology, and (ii) a conceptual basis for advancing new pipeline 
products in the emerging field of pathotropic medicine.        
2. Setting the stage – targeting metastasis, one of the gravest medical needs 
The problem of managing metastatic cancer, with its accompanying progression to 
evermore aggressive forms of the primary tumor cell (Bacac and Stamenkovic, 2008; Wong 
et al., 2009), remains one of the most daunting problems of modern medicine, thereby 
defining an unmet medical need. While many primary tumors can be eradicated by surgery 
if detected early in the course of disease progression, the appearance of metastatic disease is 
associated with a poor prognosis that worsens with the development of resistance to 
conventional chemotherapies (O’Day and Gorlick, 2009; Box et al., 2010; Verma et al., 2011). 
In the past ten years, there has been a frustrating lack of clinical advancements in the 
treatment of metastatic cancers (Di Marco et al., 2010, Stathis and Moore, 2010, Nieto et al., 
2008). Once metastatic disease develops in pediatric sarcomas or in breast cancer, for 
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example, the possibility of a cure is very limited or practically nonexistent (Krishnan et al., 
2005; Gonzalez-Angulo et al., 2007). Moreover, this decade-long frustration has resulted in 
regulators, clinical investigators, and practicing oncologists effectively lowering their 
standards and expectations with regard to clinical trials and patient outcomes (Nieto et al., 
2008; Allen et al., 2010; Verma et al., 2011). It is in this context that the call for innovative 
molecular targeted therapies emerged (Cappetta et al., 2011); it is in this context that the 
theoretical capability of tumor-targeted nanotechnology advanced (Gordon and Hall, 2005; 
Zolnick et al., 2010; Shapira et al., 2011); and it is in this context that the promise and 
potential of genetic medicine became apparent (Gordon et al., 2008; Sreeramoju and Libutti, 
2010; Gordon and Hall, 2010). 
At the turn of the 21st century, the advent of targeted genetic medicine faced three major 
challenges: (i) undeveloped biotechnology—specifically, the problem of inefficient gene 
delivery in vivo; (ii) institutional incredulity—regarding the feasibility of achieving tumor-
targeting under physiological conditions; and (iii) scientific skepticism—concerning the 
seemingly overwhelming bio-mathematics of the applied nanotechnologies required for 
effective tumor control. The first challenge was elucidated by the pharmaceutical industry, 
as it systematically withdrew from the field of genetic medicine, stating: “From the beginning, 
the therapy’s main difficulty has been a logistical one: how to deliver enough healthy genes to the 
appropriate site and get them to stay there long enough to cure or alleviate a disease....” the 
consensus opinion being, “improved gene delivery methods are needed in order to give human 
trials a better chance of success” (Langreth and Moore, 1999). The second challenge was 
exemplified by a National Cancer Institute grant reviewer, circa 2000 (privileged 
communication), who stated that “One couldn’t possibly imagine that the systemic delivery of an 
extracellular matrix (ECM)-targeted gene delivery vector would accumulate appreciably inside a 
tumor nodule; more likely, the gene delivery would be restricted to the superficial ‘stromal’ layers, 
much like the peeling of an onion skin.”  The third challenge, that of insurmountable 
biomathematics, was addressed in a scholarly debate following a keynote presentation by 
the authors at the Cold Spring Harbor Laboratory 2001 meeting on “Vector Targeting 
Strategies for Gene Therapy.” In view of the first preclinical demonstrations of efficient, tumor-
targeted gene delivery achieved under physiological conditions in vivo, there still remained 
considerable doubt concerning the feasibility of overcoming the rigors of physiology—
dilution, filtration, immunological inactivation, fluid dynamics, and shear forces—to the 
extent needed to deliver a sufficient number of vector particles via the systemic circulation 
without utilizing infectious (self-replicating) viral components. Taken together, these formal 
challenges that prevailed at the cusp of the 21st century represented a formidable 
technological barrier to entry into the field of targeted genetic medicine, in general, and to the 
advancement of cancer gene therapy, in particular.   
One by one, these imposing biopharmaceutical challenges were addressed and overcome 
during the course of a decade of scientific discovery, biotechnological innovation, 
translational research, and clinical development: a decade which may, in retrospect, be 
appropriately regarded as the decennium mirabilis of targeted genetic medicine—that 
“remarkable decade” wherein the clinical promise and potential of cancer gene therapy was 
ushered across the threshold of history. In technical scope, these challenges ranged from 
basic and applied molecular-genetics and virology, to medical nanotechnology, to the 
biophysics of tumor targeting and the constructs of therapeutic gene-delivery, to the advent 
of pathotropic (disease-seeking) medicine and the advancement of precision-targeted 
retrovectors, through a series of “proof-of-concept”preclinical studies and rigorous clinical 
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trials, leading ultimately to the GMP bio-production and scale-up of the first fully-validated 
tumor-targeted gene delivery vector (i.e., Rexin-G) in accordance with the most exacting 
(U.S. FDA) demands of a Phase III/commercial oncology product. For the purposes of this 
invited review, these individual technological steps in the origination and development of 
Rexin-G for metastatic cancer are subdivided into discrete steps or critical stages of 
development that constitute the definitive biopharmacological foundations of a new field of 
medicine.  
3. The pioneering stage – basic molecular-genetic research and discovery 
“To heal him, we must touch something other than the coverlet of his bed!” exclaimed Ambroise 
Paré in 1569, extolling those physicians and surgeons in attendance that M. le Marquis de 
Auret was not yet beyond hope, but they would have to dig somewhat deeper into the 
fabric of nature to uncover a cure. This paternal challenge from one of the great pioneers of 
experimental medicine still echoes through the ages, compelling would-be healers to look 
beyond the superficiality and the plasticity of cellular signal transduction unto the final 
common pathways that function as prime executive regulatory mechanisms governing cell 
growth and viability. Indeed, after years of disappointing studies of experimental 
treatments for vascular proliferative disorders based on the disruption of cell receptor-
mediated events, there emerged the appeal to look deeper—through an epoch of molecular-
genetic research and discovery—for the executive enzymatic components of cellular growth 
control and those final common, highly-conserved biochemical pathways that physically 
execute the orderly progression of the mammalian cell division cycle (Siriam and Patterson, 
2001; Ferguson and Patterson, 2003). It is in this deeper mechanistic understanding of the 
executive ‘enzymatic engines’ of the mammalian cell division cycle (Schwartz and Shah, 
2005; Marretta and Ales, 2010), that the drug targets of a more effectual apothecary for both 
vascular proliferative disorders (Charron et al., 2006) and otherwise intractable cancers can 
be found (Johnson and Shapiro, 2010; Krystof and Uldrijan, 2010).  
Located at the headwaters of oncogenesis, where growth-promoting proto-oncogenes meet 
and physically inactivate the predominant endogenous tumor suppressor proteins (Sherr 
and McCormick, 2002), a class of inducible regulatory proteins called “Cyclins” reside—
along with their Cyclin-dependent, proline-directed protein kinase (CDK) partners (Hall 
and Vulliet, 1991; Pines, 1995) and their respective polypeptide CDK inhibitors, which 
themselves represent a potent form of physiological growth inhibition/tumor suppression 
(Viallard, et al., 2001; Wesierska-Gadek et al., 2011). In the course of the mammalian cell 
division cycle, the Cyclins appear in a sequential manner, in accordance with the 
progressive stages of the cell cycle [note, the alphabetical designation Cyclins A through G 
denotes the order of scientific discovery/cloning, rather than the temporal induction of the gene 
product per se], participating directly in the enzymatic activation of one or more cognate 
CDKs (Gerard and Goldbetter, 2009) while physically guiding the activated protein kinase 
complexes to specific substrates (first demonstrated by Peeper et al., 1993) and subcellular 
locations (Morgan, 1997). The operational result of progressive Cyclin expression and 
resulting CDK activation can be viewed conceptually as “feed-forward” regulatory control, 
overriding endogenous growth/tumor suppressor proteins and advancing the cell cycle 
beyond the limiting biochemical checkpoint(s). The reported incidence of specific Cyclin 
over-expression, gene amplification, and/or viral subversion of these Cyclin-dependent 
pathways, in association with the molecular mechanisms of carcinogenesis, are sufficient to 
www.intechopen.com
 Gene Therapy Application 
 
464 
warrant the formal designation of proto-oncogene to describe the growth-promoting role of 
these executive regulatory elements. 
4. The mechanistic stage – molecular-genetic target validation 
Among the so-called Cyclins, the CYCG1 gene encoding human Cyclin G1 (Wu et al., 1994) 
is of particular bio-pharmaceutical importance; for it represents the molecular target of 
Rexin-G, the first targeted, injectable genetic medicine developed for diverse cancer 
indications. Indeed, recent clinical demonstrations of the broad-spectrum, single-agent, anti-
tumor activity of Rexin-G have generated intense medical and scientific interest in the 
regulatory biology of Cyclin G1, as well as the molecular mechanisms-of-action of Rexin-G. 
In the course of its pharmaceutical development, it should be noted that the advanced 
molecular-genetic “knockout” construct embodied in Rexin-G is not dependent on the 
mechanisms of antisense-mediated gene suppression—which could possibly be overcome 
by the plasticity and the redundancy inherent in the Cyclin/CDK control elements as 
structurally- and functionally-related families of genes (Malumbres, 2005; Santamaria and 
Ortega, 2006; Satyanarayana and Kaldis, 2009)—but rather Rexin-G enforces the expression 
of a dominant-negative construct, i.e., a mutant form of the Cyclin-G1 protein, which 
effectively “blocks” the executive biochemical pathways governed by Cyclin G1, in the presence 
of a veritable “sea” of wild-type protein expression (see Xu et al., 2001). It is the blockade of 
these executive biochemical pathways (shown diagrammatically in Figure 1) that is invariably 
cytocidal to cancer cells and their associated proliferative neovasculature (Gordon et al., 
2000, 2001; Gordon and Hall, 2010).  
Mechanistically, the Cyclin G1 proto-oncogene is appreciably over-expressed in numerous 
cancers; its enforced expression promotes cell growth and effectively shortens the cell cycle 
(Smith et al., 1997), while its blockade by either antisense oligonucleotides or dominant-
negative mutant constructs is decidedly lethal—via the active mechanisms of apoptosis—to 
both proliferative vascular cells (Zhu et al., 1997; Xu et al., 2001) and to a broad spectrum of 
cancer cells derived from all three germ layers (Skotzko et al., 1995; Chen et al., 1997; Hung 
et al., 1997; Gordon et al., 2001; Gordon et al., 2007; Gordon and Hall, 2010). Notably, in 
Cyclin G1-deficient mice, there is a significant reduction in the observed incidence of 
chemically-induced tumorigenesis (Jensen et al., 2003), which is consistent with a loss of 
antagonistic Cyclin G1-mediated effects on the levels and activities of the p53 tumor 
suppressor protein. As shown in Figure 1 (below), there is an intimate “negative-feedback” 
relationship between Cyclin G1 and at least two of the most prominent tumor suppressor 
proteins characterized to date: that is, the Retinoblastoma (Rb) tumor suppressor protein, 
which is genetically dysfunctional in many types of cancer, and the p53 tumor suppressor, 
which governs both apoptosis and senescence, in addition to regulating pivotal biochemical 
checkpoints involving DNA damage and enzymatic repair. In the first case, it appears that 
Cyclin G1, which is capable of forming complexes with multiple CDK partners (Piscopo and 
Hinds, 2008), participates in the inactivation of the Rb protein by directing site-specific 
protein phosphorylation events that ultimately enable cell cycle progression. In the second 
case, it appears that Cyclin G1 inactivates p53 (Ohtsuka et al., 2003, 2004), at least in part, by 
activating the MDM2 oncoprotein, which initiates the ubiquitin-mediated protein 
degradation of the p53 protein (Kimura and Nojima, 2002; Feng et al., 2011). In this case, it is 
important to note that both the Cyclin G1 effector and the MDM2 oncoprotein are 
transcriptionally activated (induced) by p53-dependent mechanisms (Okamoto and Beach, 
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1994; Moll and Petrenko, 2003), yet both of these regulatory proteins clearly function 
through additional biochemical pathways that are entirely independent of p53 (Zhang et al., 
2005; Rayburn et al., 2009), which is genetically altered and/or inactivated in a large number 
of cancers.   
Perhaps the most important aspect of target validation that can be discerned for Cyclin G1 
as a drug target—and thus Rexin-G as an anti-cancer agent—is the recent finding that nature 
itself has seen fit to target this executive regulatory locus through endogenous microRNAs 
(Feng et al., 2011; Huang and He, 2011) that exert stringent control of Cyclin G1 expression. 
A series of high-throughput screens investigating the role of microRNAs in the pathogenesis 
of human hepatocellular carcinoma (HCC) identified miR-122 as the preeminent species of 
microRNA that is either missing or severely down-regulated in approximately 70% of HCC 
cancers and in all of the HCC-derived cancer cell lines (Gramantieri et al., 2007). 
Importantly, these studies identified Cyclin G1 as a gene target of miR-122, further 
validating the inverse correlation between miR-122 and Cyclin G1 expression that exists in 
primary liver carcinomas. Assuredly, the biochemical mechanism by which miR-122 
expression decreased the viability of liver cancer cells was determined to be via apoptosis 
(Wu et al,. 2009); and enforced expression of miR-122 by adenoviral vectors has been shown 
to induce both cell cycle arrest and apoptosis in a number of different cancer cell lines (Ma et 
al., 2010) .  
It was further determined that the pathological loss of miR-122 expression in liver cancer 
was not only correlated with an increased proliferative potential of the cancer cells, but with 
the extent of disease progression and metastasis (Coulouarn et al, 2009); while the re-
expression of miR-122 was demonstrated to inhibit both the tumorigenic properties (Bai et 
al., 2009) and the metastatic potential (Tsai et al., 2009). In terms of molecular-genetic 
mechanisms of action, it was confirmed that, by modulating Cyclin G1 expression, miR-122 
influences the stability and the transcriptional activity of p53, as it reduces the metastatic 
invasiveness of HCC-derived cell lines (Fornari et al., 2009). Moreover, the inhibitory effect of 
experimentally-restored miR-122 expression on Cyclin G1 levels serves to increase the 
sensitivity of HCC cells to doxorubicin-induced apoptosis, thereby establishing a 
mechanistic basis for the future development of combined chemotherapy and RNA-based 
cancer therapies. Taken together with the emerging molecular biology of Cyclin G1 (see 
Figure 1), it now appears that the biopharmaceutical agent, Rexin-G (a RNA-based genetic 
medicine), essentially restores a natural tumor suppressor function that is inherent in a 
normally-abundant species of microRNA—a species of microRNA that is lost with the 
pathogenesis of cancer, particularly that of invasive metastatic cancer.  
Fig. 1 legend: As a mitotically-activated (or transformed) cell becomes ‘competent’ to 
proliferate and  passes through the sequential phases of cell growth and DNA synthesis on 
to cell division, Cyclin G1 plays a pivotal role in governing the executive enzymatic 
activities of  key regulatory components, including the checkpoints sensing DNA damage 
and repair. Normally held tightly in check (by microRNA-122), the growth-associated 
Cyclin G1 stands at the headwaters of cell cycle progression: advancing the cell cycle 
(arrows) through a myriad of enzymatic complexes, (i) by regulating site-directed protein 
phosphorylation by cyclin-dependent protein kinases (CDKs), which phosphorylate and 
inactivate the Rb tumor suppressor protein (blunted arrows), and (ii) by activating the 
cellular oncoprotein MDM2, which in turn inactivates the p53 tumor suppressor protein 
(blunted arrows) by initiating its destruction. Cyclin G1 governs the enzymatic activities of 
such key regulatory enzymes by transcriptional control of downstream elements, enzymatic 
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activation/inactivation of the executive enzymes, and by directing the regulatory complexes 
to specific substrates and/or specific subcellular locations.  
 
 
Fig. 1. Diagram depicting the major enzymatic activities, proto-oncogenes, and tumor 
suppressor proteins operating in the executive biochemical pathways governed by Cyclin 
G1.  
 
 
Fig. 2. Retroviral vector-mediated gene transfer of an antisense Cyclin G1 construct inhibits 
osteosarcoma growth in nude mice.  
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Following the identification of Cyclin G1 as a strategic therapeutic locus, a series of 
preclinical studies provided the initial proofs-of-concept (Skotzko et al., 1995; Chen et al., 1997; 
Gordon and Hall, 2010), thereby validating the therapeutic potential of cyclin G1 
“knockout” constructs as anti-cancer agents by direct injection of therapeutic gene-delivery 
vehicles, or vectors, into tumor xenografts in experimental animals. As shown in Figure 2, 
both the reduction of tumor growth and the accompanying blockade of cell cycle 
progression are readily apparent. However, the more pressing technological challenge to 
reach beyond the obvious accessibility of localized primary tumors, and to address the 
fundamental problem of metastatic disease—i.e., to deliver the therapeutic potential of 
Cyclin-G1 knockout constructs where they are needed most—remained to be accomplished 
by a separate and distinct stage of scientific innovation.  
Fig. 2 legend: Down-regulation of Cyclin G1 expression inhibits the proliferation of human 
osteosarcoma cells, as shown in rapidly growing subcutaneous tumors in athymic nude 
mice (Left Panel) treated by direct injection of either a Control (A) or Antisense Cyclin G1 
vector (B); comparative tumor growth over time is shown in C. Histological analysis of 
tumor nodules (Right Panel) from Control (A,C,E) versus Antisense Cyclin G1 treated 
animals (B,D,F) demonstrates a significant reduction in the mitotic index in Antisense Cyclin 
G1-treated animals, which is confirmed by FACS analysis (E vs F), revealing a decrease in 
the number of cells in S and G2/M phases of the cell cycle (Chen et al., 1997). Cytocidal 
activity is confirmed by an increased incidence of apoptotic nuclei in the Antisense Cyclin 
G1-treated osteosarcoma cells (Skotzko et al., 1995).  
5. The advent of pathotropic targeting – an enabling therapeutic gene 
delivery platform 
In the course of scientific research and development it is often “The Road Not Taken,” that 
is, the conscious decision to take the road less traveled by, that turns out to make the most 
significant difference in terms of historical outcome. In the case of targeted gene delivery, it 
was the conscious decision to target a common histopathological property of the metastatic 
process, rather than the unique and ever-changing surface features (ligands, receptors, etc) 
of the individual cancer cells, that made all the difference in terms of enhancing the 
efficiency of tumor-targeting under the most demanding of physiological conditions. 
Indeed, in the process of metastasis and metastatic tumor formation, both nascent and 
underlying extracellular matrix (ECM) proteins are characteristically exposed; and it is this 
characteristic exposure of one particular class of ECM proteins, the ubiquitous and 
determinative collagens (i.e., collagen patefacio, from Gordon and Hall, 2009), that now forms 
the basis for disease-seeking (or Pathotropic) tumor targeting. By conceptually grasping the 
physiological surveillance function that is inherent in the von Willebrand blood coagulation 
factor (vWF), which normally guides platelets to the sites of vascular injuries, and then 
physicochemically transposing a synthetic derivative of this physiological surveillance function, 
via genetic engineering, onto the surface of a nanoparticle-sized gene delivery vector (Hall 
et al., 2000; Gordon et al., 2000, 2002), the fields of molecular biotechnology and 
nanotechnology converged to enable the medical oncologist to reach beyond the mere 
coverlets of the proverbial bedside and to expose the very fabric of the nature of the 
metastatic disease process (Gordon and Hall, 2005, 2007). It is the advent of pathotropic 
targeting which would ultimately serve as the enabling biotechnological platform for 
therapeutic gene delivery in vivo, enabling the development of tumor-targeted gene therapy 
vectors that could be administered systemically, which would then seek-out sites of 
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cancerous histopathology and accumulate to high levels in primary tumors and in the 
remote, occult, and otherwise inaccessible lesions of cancer metastasis.  
6. The definitive proofs of principle - targeting metastasis in vivo in pertinent 
models of cancer 
Comprised of (i) a structural multi-lamellar capsule (or retrovector core), (ii) a genetic 
payload of various designs, and (iii) a pathotropic envelope protein, the first tumor-targeted 
gene delivery vectors were initially designed to carry unique “marker genes,” in the place of 
a therapeutic RNA construct, in order to study the kinetics and biodistribution of the 
circulating nanoparticles under well-defined experimental conditions, as well as the overall 
efficiency of the resulting gene transfer events. As shown in Figure 3 (below), which depicts 
a classic subcutaneous tumor xenograft model in which human tumor cells are flagrantly 
grafted into the flanks of athymic mice, the tumor-targeted vector is subsequently 
introduced into the systemic circulation through the tiny tail vein of the sleeping animal. 
The tumor-targeted nanoparticle must not only withstand the intense turbulence and 
dilution of the general circulation in this model, it must transit the heart, pass through the 
extensive filtering networks of the lungs, and transit the heart once again, before it is 
pumped through the aortic arch and a mere fraction of the blood flow is distributed to the 
flanks on the first pass. Nevertheless, the targeted nanoparticles are demonstrably 
partitioned into the tumor xenografts within a matter of minutes with intense avidity, where 
they can be seen to leave the fenestrated circulation within the tumors and begin to spread 
throughout the tumor nodules,  much like a particulate dye accumulates from solution (by 
high affinity) into a natural sponge. With this constant pathotropic partitioning and 
resulting accumulation of vector particles in high local concentrations within the tumor 
nodules, it is clear that the targeted nanoparticles are highly active in terms of effectuating 
marker gene delivery to the proliferative cancer cells, as evidenced by the quantitative 
efficiency of the resulting transgene expression.   
 
 
Fig. 3. Redistribution and gene transfer activity of a tumor-targeted retrovector bearing a 
marker gene into subcutaneously-implanted tumor xenografts in athymic mice. 
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Fig. 3 legend: Human pancreatic cancer cells were implanted in this classic cancer model 
(Left Diagram) followed by intravenous infusions of a tumor-targeted gene transfer vector 
(+) or non-targeted control vector (-). Immunohistochemical staining for the retrovector 
envelope protein (Right Panel) demonstrated appreciable accumulation of the targeted 
vector within 60 minutes of infusion (brown stain, A), which can be seen spreading out from 
the vasculature into the interstitial matrices of the tumor nodule (higher magnification, B, 
and C), in comparison with the non-targeted control vector where little if any accumulation 
can be found. Immunohistochemical staining for the β-galactosidase marker gene (Lower 
Left) confirmed high levels of transgene expression with the targeted vector. 
Moving on to a somewhat more pertinent model of metastatic pancreatic cancer, where 
metastasis to the liver is all too common, additional characterization of the physiological 
surveillance function of these tumor-targeted nanoparticles was revealed, along with a 
striking demonstration of the high degree of selectivity of this targeted gene delivery 
platform for tumor cells and their associated neovasculature, while sparing normal liver 
cells in the immediate vicinity. In the model of metastatic pancreatic cancer shown in Figure 
4 (below), the tumor-targeted retrovector bearing the designated marker gene was instilled 
at certain stages following the development of the liver metastasis. In the earliest stages of 
metastasis, where small groups and clusters of cancers cells invade the liver—before a 
distinctive tumor nodule is apparent – the vector demonstrates a striking ability to follow 
the submicroscopic biochemistries of tumor cell invasion, tracking the path of the invasive 
cancer cells, and delivering its transgene payload (marker gene) selectively to the invasive 
tumor cells while sparing the normal liver parenchyma. With the onset of neoangiogenesis, 
it becomes clear that, in addition to delivering the marker gene to the proliferative tumor 
cells, the pathotropically-targeted vector efficiently targets the vasculature of these 
aggressive tumors as well; thus the major focus of the transgene gene delivery is restricted 
to metastatic cancer cells and their attendant blood supply. These findings further indicate 
that an appropriate therapeutic (i.e., cytocidal) payload would exhibit significant anti-
angiogenic properties, as well as anti-tumor activities. 
   
 
Fig. 4. Pathotropic vector bearing a marker gene identifies cellular targets for gene transfer 
in a murine model of pancreatic cancer metastatic to the liver.  
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Fig. 4 legend: Human pancreatic cancer cells were infused via the portal vein into the liver 
(Left Panel) followed, three days later, by portal vein infusions of a tumor-targeted gene 
transfer vector bearing a β-galactosidase marker gene at various stages of tumor formation 
(Right Panel). H&E staining of the earliest stage of metastasis (A) shows a small group of 
pancreatic cancer cells exiting a hepatic vein and migrating into the liver parenchyma. 
Histochemical staining for the marker gene expression (blue-green stain in B, enlarged in C) 
demonstrates efficient and selective gene delivery to the cancer cells. Following the 
establishment of the liver tumors with onset of neoangiogenesis (H&E stain of vessels 
shown in D), transfer of the β-galactosidase marker gene is seen in the proliferative 
endothelial cells of the tumor vessels (E and F). 
Replacing the marker gene cassette with a cytocidal dominant-negative Cyclin G1 construct 
resulted in the development of the therapeutic anti-cancer agent designated Rexin-G, an 
acronym that conveys its molecular engineering roots:  Retroviral expression vector bearing an 
inhibitory construct of the Cyclin G1 gene. Pioneering studies in the aforementioned preclinical 
cancer models with this killer gene as the genetic payload, resulted in the first 
demonstrations of clinical efficacy for targeted gene delivery in vivo: (i) corroborating the 
high-efficiency of tumor-targeted gene delivery with evidence of clinical efficacy, (ii) 
establishing the initial dose-response curves of an emergent pharmacology, (iii) confirming 
the fundamental biochemical mechanisms-of-action as enforced apoptosis, and (iv) 
revealing the characteristic hallmarks of tumor destruction and regression under the 
onslaught of this targeted cytocidal genetic medicine. As shown in Figure 5, repeated 
intravenous infusions of Rexin-G administered in a tumor xenograft model induced 
significant inhibition of tumor growth while altering the entire histology of the residual 
tumor nodules: as areas of focal vascular destruction (anti-angiogenesis) and massive tumor 
necrosis are observed among distinctive zones of overt cellular degeneration and reparative 
fibrosis.  
 
 
Fig. 5. Repeated intravenous infusions of Rexin-G abate the growth and alter the histology 
of pancreatic cancer xenografts in athymic mice.  
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Further histological analysis confirms that the major mechanism-of-action responsible for 
the observed tumor destruction is the induction of apoptosis by Rexin-G, which is evident in 
both the cancer cells and the endothelial cells of the associated tumor neovasculature. In 
addition to these histological indications of tumor destruction attributed to Rexin-G 
(Gordon et al., 2000, 2001) is the recruitment of tumor infiltrating  lymphocytes to clean up 
the resultant tumor debris (see Figure 6).  
Fig. 5 legend: Human pancreatic cancer cells were established as subcutaneous xenografts in 
the flanks of the experimental animals, followed one week later, by tail vein infusions of a 
tumor-targeted Rexin-G or a non-targeted vector (as indicated). Histological analysis of 
tumors from control vector- (A,B) versus Rexin-G vector-(C-F) treated animals (Left Panel) 
showed massive and focal necrosis (n) of tumor cells (t), along with zones of vascular 
disruption (C), and fibrosis (F). TUNEL staining for the detection of DNA fragmentation 
(Right Panel) confirmed the primary mechanism-of-action to be apoptosis (brown stain, 
arrows), which is rare in control tumors (A) with their robust vascular beds (B), but is 
readily evident in the disrupted vasculature (C,D) and in the dying tumor cells (E,F) of the 
Rexin-G treated animals.  
 
 
Fig. 6. Complete eradication of liver metastases by repeated infusions of Rexin-G retrovector 
in a murine model of metastatic pancreatic cancer.  
Fig. 6 legend: Flagrant tumors are shown in control animals (A, enlarged in C) vs no 
evidence of active tumor cells in Rexin-G –treated mice (B, enlarged in D). Note: Resident 
Kupffer cells (macrophages in the liver) are observed to be engorged with hemosiderin 
indicative of phagocytosis of tumor debris. Analysis of dose-response (Gordon et al., 2000), 
in relation to inhibition of tumor growth, formed the basis of a more-predictive clinical 
pharmacology. 
7. The 1st clinical stage – phase I studies establish clinical feasibility and 
overall safety 
The definitive demonstrations of selective tumor targeting, predictable mechanisms-of-
action, and single-agent efficacy in preclinical cancer models provided compelling impetus 
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for expedient clinical development, which necessitated further evaluations of general safety, 
dose-response relationships, bio-distribution, pharmacokinetics, and monitoring of gene 
transfer in a series of scientific studies that ranged from mice, to rats, to rabbits, to larger 
animals (pigs). Taken as a whole, the resulting compilation of scientific evidence served to 
provide the requisite documentation of general safety and the reasonable expectation of clinical 
benefit that was critically analyzed by the NIH Recombinant DNA Advisory Committee 
(RAC), which was formed in 1974 in response to public concerns regarding the safety of 
manipulating genetic material through the use of recombinant DNA techniques. In 
accordance with its role as a federal advisory committee, the RAC forwarded its 
recommendations to the Director of the Office of Biotechnology Activities, in line with the 
General NIH Guidelines for basic and clinical research involving recombinant DNA 
molecules and human gene transfer trials, respectively. Critical review and analysis of 
scientific, safety, and ethical considerations by the RAC pertaining to the clinical utility and 
administration of Rexin-G in humans, was conducted in 2000 (Lenz et al., 2002) at which 
time, the appointed reviewers stated that the platform targeting biotechnologies embodied 
in Rexin-G were both elegant and important (Russell, RAC Transcript, 2000).  
While it was initially envisioned that Rexin-G would be administered to human cancer 
patients regionally at first, via hepatic arterial infusions (Lenz et al., 2002), it so happened 
that a series of formal requests for Compassionate Use applications of Rexin-G in Stage IV 
metastatic pancreas cancer took precedent—in compliance with both U.S. FDA permissions 
and Philippine BFAD/FDA regulations—which served to propel the clinical advancement 
of Rexin-G. In terms of time, it served to validate the tumor-targeted gene delivery platform 
as a systemically administered agent. With federal allowances for such commendable 
international collaboration in place, Rexin-G was first deployed in the clinic in the 
Philippines in 2002, with the tacit acknowledgement that Epeius Biotechnologies would 
advance its clinical development program in the USA “as soon as practicable” (U.S. FDA 
Communications, 2002).  
These pioneering clinical studies of Rexin-G in chemotherapy-resistant pancreatic cancer 
(Gordon et al., 2004) stand as the seminal foundations of targeted genetic medicine by (i) 
demonstrating the safety and single-agent anti-tumor activity of repeated intravenous 
infusions, (ii) affirming predicted dose-response relationships astutely extrapolated from 
pertinent preclinical data, and (iii) validating the tumoricidal mechanisms-of-action of 
Rexin-G, along with the now-classical hallmarks of tumor destruction (see Figure 7). 
Fig. 7 legend: Combined PET-CT scan (Left Plate) shows central necrosis in 5 out of 6 visible 
lesions in one patient with chemo-resistant pancreatic cancer. An opportunistic surgical biopsy 
of a liver lesion after Rexin-G treatment (Right Plate) in another patient with chemo-resistant 
metastatic pancreatic cancer reveals characteristic zones of anti-angiogenesis (A), along with 
focal necrosis of tumor cells (A,B), overt apoptosis, verified by TUNEL stain (D,E), reparative 
fibrosis (A-f, Mason’s Trichrome in C), and recruitment of tumor-infiltrating lymphocytes (F), 
including CD4+ helper (stained in F) and CD8+ killer T-cells (not shown). 
The authors’ report of unprecedented single-agent anti-tumor activity of Rexin-G observed 
in 3 out of 3 pancreatic cancer patients who were treated in the Philippines with increasing 
weekly doses of Rexin-G in an innovative intra-patient dose-escalation regimen—where careful 
analysis of drug safety was verified before escalating to progressively higher doses—gained 
Orphan Drug Designation for pancreatic cancer by the U.S. FDA in 2003, and federal 
funding from the FDA Orphan Products Development program in 2006. The first U.S.-based 
Phase I study established the overall safety of repeated infusions of Rexin-G and the lower 
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rungs of the pharmacological dose-response curve for Stage IV pancreatic cancer (Galanis et 
al., 2008) compared to the higher, more-effective doses shown in succeeding advanced 
Phase I/II studies (shown in Figure 11; Chawla et al., 2010). Meanwhile, clinical 
development of Rexin-G advanced in the Philippines through a series of Phase I/II studies 
and an Expanded Access program, which extended the scope of clinical applications to a 
wider variety of cancers, including breast cancer, melanoma, and laryngeal CA (Gordon et 
al., 2006, 2007).  
 
 
Fig. 7. Radiological and histological evidence of anti-tumor activity of Rexin-G.  
 
Fig. 8. Tumor-targeted nanoparticles extend physiological reach and clinical efficacy into the 
lymphatic system.  
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Among the most important insights gained from these pioneering clinical studies—insights 
which were not immediately apparent from the preclinical models—was the finding that the 
physiological surveillance function inherent in the Rexin-G nanoparticles was not only 
capable of targeting tumors by successive excursions through the general circulation, but 
was also capable of penetrating and eliminating cancer metastases in the lymphatic system 
(see Figure 8).  
Fig. 8 legend: Biopsy of a surgically excised lymph node (Left Plate) in a patient with 
metastatic malignant melanoma exhibits the characteristic hallmarks of Rexin-G mediated 
tumor destruction along with its apoptotic mechanisms-of-action (legend). Monitoring 
stabilization of disease (SD), along with the observed decrease in the size and extent of 
lymph node metastasis (B) in a Stage IVb pancreatic cancer patient (Right Plate) 
encouraged clinical oncologists to “hold the course” of Rexin-G treatment, even in the face 
of slight progressive disease (PD) seen in the liver (A); an astute clinical decision that 
resulted in a clinical remission, initially observed after 9 months of Rexin-G treatment. 
Note: remission/survival ongoing > 2 yrs. 
8. The 2nd clinical stage – phase II studies establish the molecular 
pharmacology  
With the clinical feasibility and general safety of the Rexin-G retrovector formally 
established in the clinical setting, the U.S. FDA approved the stepwise escalation of Rexin-G 
dosage in a series of three adaptive and advanced Phase I/II studies for metastatic 
chemotherapy-resistant pancreas cancer, sarcoma, and breast cancer. The adaptive study 
designs were intended to further refine the analysis of Rexin-G bioactivity, in terms of 
pertinent tumor response criteria, while these inter-patient dose escalation studies were 
advanced, in as much as a Phase II evaluation of clinical efficacy was incorporated in each of 
the study designs. These studies demonstrated that Rexin-G was well tolerated, with no 
evidence of dose-limiting toxicities (DLT), and that Rexin-G exhibited dose-dependent anti-
tumor activity when administered as a stand-alone therapy for pancreatic cancer and 
sarcoma (Chawla et al., 2009, 2010). Of particular importance was the availability of surgical 
specimens obtained during the course of Rexin-G treatment, where Rexin-G was permitted 
by study design to serve as both neoadjuvant therapy, to bring the cancer under control, and 
as post-surgical adjuvant therapy, to help prevent recurrence. The availability of such 
germane and opportune histology served to validate the predictable molecular and 
histological mechanisms of Rexin-G action (Hall et al., 2010; see Figure 9 below). 
Fig. 9 legend: Immunostaining for the vector nanoparticles (Left Plate) demonstrates the 
generalized accumulation of vector particles within the tumor (light brown staining material 
A, versus Control, with no primary antibody B); moreover, the natural propensity/targeting 
of the retrovector envelope for the phosphate transporters that are abundant on proliferative 
cells results in targeting of tumor cells and associated vasculature (C-E). Right Plate: 
Immunostaining for Keratin identifies the islands tumor cells (A, insert) amidst extensive 
fibrosis (B, Trichrome stain), while TUNEL stain verifies active cancer cell death by 
apoptosis (C, D versus Control E). It is relevant to note that this patient with metastatic 
pancreatic cancer has enjoyed a sustained surgical remission with adjuvant Rexin-G therapy 
for over 2 years. 
In the course of these advanced, adaptive Phase I/II studies, the clinical responses to Rexin-
G were examined in a  comprehensive manner, which included an analysis of tumor size 
(RECIST criteria), metabolic activity (International PET criteria), and changes in tumor 
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density (CHOI criteria). From this, it was possible (i) to discern early tumor responses to 
Rexin-G treatment (recall Figure 7) in relation to its tumor-targeted mechanisms-of-action, 
and (ii) to refine the evaluation of clinical efficacy (previously established as RECIST for 
cytotoxic chemotherapy) and to apply more pertinent evaluation criteria to the emerging 
field of targeted biologics. In the case of an osteosarcoma patient, for example, the use of 
 
 
Fig. 9. Immunohistochemical staining of sections of a biopsied liver nodule obtained during 
Rexin-G treatment, revealing tumor-targeting and tumor-destroying mechanisms-of-action.  
 
Fig. 10. Demonstration of dramatic anti-tumor activity of Rexin-G as monotherapy for 
osteosarcoma (by PET/CT scans) and dose-dependent overall survival time by analysis of a 
Phase I/II clinical study of Rexin-G in bone and soft tissue sarcomas.  
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RECIST criteria for evaluating tumor response was not reliable, since clinical efficacy was 
characterized more appropriately by the reduction in tumor metabolic activity (by PET 
scan), accompanied by extensive calcification of tumor nodules (see Figure 10). 
Based on these findings, the U.S. FDA approved a Phase II study for osteosarcoma to be 
conducted concomitantly with the ongoing Phase I/II study for bone and soft tissue 
sarcomas (STS) that used the PET scan as the primary imaging tool for the evaluation of 
clinical efficacy. Aggregate analysis of these study results confirmed the overall safety of 
Rexin-G (with no DLT), its anti-tumor activity, and the positive dose-dependent impact on 
patient survival parameters (Figure 10) which, after all, represents a “gold standard” for the 
evaluation of clinical responses for a prospective anti-cancer agent. 
Fig. 10 legend: Left Panel: Radiological examination of a 17-year old male patient after 
primary tumor excision and limb salvage surgery (A) reveals rapidly progressing 
metastases (insert) to lung and adrenal gland. Rexin-G infusions halted tumor progression, 
as evidenced by no new lesions, a significant (48%) reduction in tumor metabolic activity 
and overt calcification of the target lesions shown in follow-up PET-CT scans during Rexin-
G treatment (baseline B, versus C and D). Right Panel: Analysis of the Phase I/II  study data 
demonstrates a dose-dependent increase in patient survival parameters.   
In these Phase I/II and Phase II studies of clinical safety and efficacy, it became increasingly 
evident that the observed dose-response phenomenology, as well as the predicted Calculus 
of Parity (Gordon et al., 2006; Gordon and Hall, 2007), had served to establish the basic 
foundations of an emerging clinical pharmacology for Rexin-G, providing estimates of 
optimal weekly doses, by determining the quantitative threshold for bioactivity for both 
pancreas cancer and sarcomas; and providing a practical estimate of the actual numbers of 
nanoparticles needed on a weekly basis to match an aggressive, chemotherapy-resistant 
tumor burden and, thus, to impact the fatal course of metastatic disease. This emergent 
clinical pharmacology has several important implications: First, it serves to address and to 
resolve the problem of exponential tumor cell growth, with the conclusion that it is indeed 
difficult, but not impossible, to provide sufficient numbers of targeted nanoparticles needed 
to meet and match a given tumor burden. Second, it affirms that chemo-resistant cancer 
patients do indeed die, as predicted, in the absence of sufficient quantitative intervention, in 
accordance with the results of the Rexin-G low-dose safety studies and the historical 
controls (see Figures 10 and 11). Most importantly, by establishing the quantitative 
pharmacology of Rexin-G action in end- or late-stage chemo-resistant cancer, these seminal 
Phase I/II dose-escalation studies serve to establish critical analytical parameters and 
meaningful benchmarks for further clinical studies—studies that will extend the utility of 
Rexin-G to additional types of solid tumors, to surgical oncologists who will employ it as 
neoadjuvant/adjuvant therapy to effectuate a curative surgery, to clinical oncologists who 
will deploy it in combination with other useful anticancer agents, and eventually to many 
cancer patients at much earlier stages of the disease, where the respective tumor burden 
could be matched and can no longer be considered either unreachable or insurmountable. 
9. Regulatory considerations – efficacy & safety as the basis of 
pharmacology / toxicology 
The conduct and the progression of clinical trials for an investigational new drug (IND) are 
carried out under stringent oversight by the clinical investigators, the medical and scientific 
authorities of the corporate sponsor, and the local and federal regulatory agencies, the latter 
of which provide an additional level of critical analysis and assurance that adequate safety 
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considerations have been achieved prior to granting approval for a given cadre of patients 
to be treated at the next higher dose level, as specified in the clinical study design. In this 
regard, it is important to note that Rexin-G exhibited an exemplary safety profile in the 
adaptive Phase I/II studies sufficient to warrant an expedited dose escalation. As 
represented graphically in Figure 11, the enrollment of chemotherapy-resistant sarcoma 
patients in the Phase I/II study happened to outpace the enrollment of patients in the Phase 
I/II study for pancreatic cancer; and, as such, the scheduled dose-escalations proceeded to 
higher, more-effective doses in a shorter period of time. However, in view of (i) the 
documented safety of each preceding dose level, (ii) the evidence of dose-dependent tumor 
control, and (iii) the survival benefits achieved in the sarcoma study, the U.S. FDA granted 
permission for an “across-the-board” dose escalation for all three ongoing Phase I/II trials in 
an effort to improve cancer control and patient outcome. An examination of the resulting 
Kaplan-Meier survival curves (see Figure 11, below) affirms the astuteness of this regulatory 
approval, whereby the critical analysis of the bone and soft tissue sarcoma patients served, 
in effect, to extend the lives of the pancreatic cancer patients. In this context, the constructive 
philosophical adage, first introduced in the FDA Centennial Book chapter “A Primer on 
Pathotropic Medicine”(Gordon and Hall, 2007), is all the more compelling:  “When the 
pathotropic medication is of broad spectrum utility, as in the case of Rexin-G, it behooves the clinical 
investigator to expand the scope of the clinical applications to include a broad spectrum of different 
intractable metastatic cancers, with the realization that—given the appropriate interim analysis—
each new patient’s experience may benefit the next, and that additional penetrating insights can be 
gained upon extensive critical analysis performed in aggregate.” Hence, it is important to consider 
that the safety and efficacy data obtained from a relatively small number of patients in clinical 
trials of this investigational new drug are, in actuality, the prime scientific building blocks 
upon which the toxicology, the pharmacology, and ultimately the praxis of targeted genetic 
medicine will be constructed.  
 
 
Fig. 11. Kaplan-Meier survival curves for two concomitant Phase I/II studies of Rexin-G 
administered as monotherapy to metastatic cancer patients who had previously failed 
standard chemotherapies.  
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Fig. 11 legend: Left Panel: Overall survival of pancreatic cancer patients is increased 
significantly from the previous Phase I safety studies (arrow) by successive dose escalation, 
which was expedited by critical analysis of an ongoing Phase I/II study of bone and soft 
tissue sarcoma (Right Panel) and subsequent allowance of an across-the-board dose escalation 
to effective clinical doses. Note, the dismal survival times observed in the lowest dose 
groups is in agreement with historical control data for each of these respective chemo-
resistant cancers; while dose-dependent gains in overall survival are clinically, statistically 
significant.    
In the Philippines, where the clinical development of Rexin-G proceeded to advance with 
similar regulatory oversight, data analysis, and guidance, the clinical studies were facilitated 
by the federal approval of an Expanded Access Program, wherein a larger and more diverse 
set of metastatic cancers – cancers originating from all three germ layers – were determined 
to be responsive to the anti-cancer bioactivity of Rexin-G. At this point, it became 
exceedingly important to standardize the GMP bio-manufacturing of Rexin-G to an even 
greater extent, and to undertake a program of research and development aimed at 
characterizing the stability of the drug product under conditions of long-term storage, which 
is measured in years. Following extensive analysis of product safety, efficacy, composition, 
purity, and long-term stability, Rexin-G was granted Accelerated Approval in 2007, 
receiving a Certificate of Product Registration from the Philippine Bureau of Food and 
Drugs (BFAD/Philippine FDA) enabling its commercialization for the treatment of all solid 
tumors that are determined to be resistant to standard chemotherapies. Thus, it is 
reasonable to expect that Rexin-G will follow a similar course of clinical development in the 
United States and worldwide, where clinical studies and regulatory oversight are 
comparable.   
Following the registration of Rexin-G for all solid chemo-resistant tumors in the Philippines, 
and the attainment of its first Orphan Drug Designation for pancreatic cancer in the U.S, the 
clinical development of Rexin-G advanced steadily in the USA with the successful 
completion of three adaptive Phase I/II studies for sarcoma, breast cancer and pancreatic 
cancer, and a Phase II study for osteosarcoma (Chawla et al., 2009, 2010); in each of these 
studies, both primary and secondary endpoints were achieved. Formal critical evaluation of 
the U.S. safety and efficacy data, with due consideration for the unmet medical need, 
resulted in the granting of two additional Orphan Drug Designations for Rexin-G – with its 
implicit market protections and clinical development priorities for soft tissue sarcoma and 
osteosarcoma. In mid-2009, Rexin-G gained Fast Track Product designation from the U.S. 
FDA as 2nd-line treatment for pancreatic cancer, to expedite the development and 
validation of the tumor-targeted gene delivery platform and its therapeutic “payload.”   
10. The commercial product – GMP production, bio-processing, QA testing, 
and scale-up 
As Rexin-G approaches the cusp of Phase III clinical trials in the USA for both pancreatic 
cancer and sarcomas, it is important to note that the clinical development of Rexin-G to date 
is a function of the multiple levels of safety and efficacy embodied in its design engineering, 
as is the observed broad-spectrum anti-cancer activity. Indeed, the molecular-genetic 
components of the Rexin-G retrovector are enhanced by the set of virtues and limitations 
inherent in the biotechnology platform, which work together to provide four distinctive levels 
of safety in coordination with three distinctive levels of efficacy (see Gordon and Hall, 2010). In 
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terms of Safety: (i) the stealth vector platform allows repeated infusions without untoward 
immunologic reactions; (ii) the limitations of the retroviral core becomes a virtue, as the 
vector is capable of enforcing gene expression in proliferative / dividing cells only; (iii) the 
growth-associated designer gene is active against cancer cells and proliferative vasculature 
but not against normal non-dividing cells; and (iv) the pathotropic accumulation in 
cancerous tissues sequesters the vector away from non-target organs. In terms of Efficacy: (i) 
the cell cycle gene knockout provides for broad-spectrum anti-cancer activity, while (ii) the 
anti-angiogenic activity destroys tumor-associated vasculature, and (iii) the pathotropic 
targeting leads to effective drug accumulation where it is needed most, i.e., in cancerous 
lesions in the vicinity of target cancer cells. In terms of the therapeutic “designer gene” it 
bears reiteration that recent studies of functional genomics using high-throughput screening 
methodologies have served to validate the Cyclin G1 locus as a critical gene target for the 
key tumor-suppressive microRNA, miR-122 (Gramanteri et al., 2007; Fornari et al., 2009), 
thereby linking the loss of this natural endogenous molecular regulation (of the Cyclin G1 
locus) to both the mechanisms of carcinogenesis (Bai et al., 2009) and the cytological 
progression of metastatic disease (Coulouarn et al., 2009). In light of such scientific 
validation of the drug target, it is increasingly apparent that, by inhibiting the executive 
oncogenic Cyclin G1 pathway in a highly selective manner, the molecular-genetic construct 
delivered by Rexin-G serves to restore a natural tumor-suppressive function that is lost or 
disabled with the onset of many cancers. In anticipation of the calculated need for higher-
potency Rexin-G formulations, along with the need to produce much larger quantities of the 
Phase III clinical grade product—which essentially becomes the commercial product—
coordinated research and development activities have focused on the large-scale 
biopharmaceutical manufacturing of Rexin-G under stringent GMP conditions, where an 
uncompromising effort was made to preserve the integrity of each and all of the structural 
and enzymatic components that constitute the functionality of the tumor-targeted 
nanoparticle, and to preserve the fidelity of the therapeutic transgene. 
Physicochemically, the Rexin-G nanoparticle is assembled from a certified bank of producer 
cells under the instructive directions of three separate gene cassettes (called plasmids):  1. 
Gag (structural), 2. Pol (enzymatic), and 3. Envelope (cell recognition and entry), which 
come together in a process called transfection to determine the unique properties of the 
synthetic retrovector particles. Namely, the nano-sized particles are replication incompetent, 
packaging only the therapeutic gene of interest; they are stealth in terms of their low 
immunogenicity, enabling repeated intravenous infusions; they are selective, capable of 
delivering the therapeutic transgene to dividing cells only; and they are pathotropically-
targeted, physically capable of seeking-out and accumulating in diseased tissues under 
physiological conditions. The use of the ‘Split Genome’ elements in biopharmaceutical 
manufacturing—i.e., the partitioning of the retrovector elements into three separate and 
distinct plasmids—renders the synthetic nanoparticles certifiably replication incompetent, 
while successive generations of R&D and improvements in plasmid structure and 
performance elevated the industry to a new state-of-the-art (see Gordon et al., 2008 for a 
review). The strategic utilization of a transient co-transfection system for the bioproduction 
of each large-scale batch of Rexin-G—as opposed to stable packaging or producer cell lines, 
which are susceptible and prone to genetic drift—is purposeful, in that it maintains all the 
refinements in retrovector design engineering in the final clinical product.  
While the myriad details of biopharmaceutical GMP protocols, optimizations of cell 
factories, post-production bio-processing procedures, qualification of bioassays, product 
identity assessments, product purity testing, and sterility certification, along with the 
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multitude of quality control and quality assurance issues and documentation that 
accompany these highly-standardized procedures is beyond the scope of this review, it 
should be emphasized nonetheless that these are among the most meticulously-prepared 
and thoroughly-documented records that are subjected to critical analysis by the FDA, 
under the auspices of Process Analytical Technology (PAT) and Chemistry, Manufacturing 
and Control (CMC) reviews. Suffice it to say that the developers of Rexin-G are in complete 
accord with the U.S. FDA’s current perspective on modern drug quality systems, which 
states, “…quality cannot be tested into products; it should be built-in or should be by design.” 
By addressing and resolving a number of serious GMP and CMC issues that had previously 
plagued the biopharmaceutical industry, in terms of the consistency, variability, and 
industrial scale-up of complex biologics to the point of commercial feasibility, the 
developers of Rexin-G demonstrated the practical utility of applied research: improving the 
overall safety, efficiency, productivity, purity, scalability, economy-of-scale, and ultimately 
the affordability of the clinical grade biologic product for the benefit of cancer patients, the 
biopharmaceutical industry, and society. 
In the context of this communication, it bears mention that the relative purity of Rexin-G, over that 
which was originally approved for use in humans and employed in years of clinical trials, has been 
increased more than 400X. In other words, the clinical product (now at 1 x 10e10 cfu/ml) is well over 
99.7% more pure in terms of allowable excipients per dose. For example, a 500ml dose of Rexin-G at 
2.5 x 10e7cfu/ml is now administered as 1.25 ml.    
In January 2011, the U.S. FDA granted Phase 3 status for Rexin-G. What this means, in terms 
of clinical development, is that the Rexin-G product, with its advanced GMP manufacturing, 
bio-processing, and final formulation, meets rigorous FDA standards for obtaining a 
marketing license in the future; and that the developers can now proceed with its strategic, 
diversified Phase 3 drug development programs for osteosarcoma, soft tissue sarcoma, and 
pancreatic cancer where it has received Fast Track Designation and Orphan drug priorities. 
11. The 3rd clinical stage – multiple phase III studies for U.S. product 
registration 
Despite the enlightened intentions of the U.S. FDA Accelerated Approval program to 
shorten the development times of promising new drugs for serious medical illness – that is, 
to grant accelerated approval for new molecular entities on the basis of compelling Phase II 
trial data, followed by confirmatory post-approval trials – there has been a discernable 
reversion, in recent years, for the U.S. FDA to restrict Phase II efficacy endpoints and to 
encourage sponsors to design accelerated approval applications on the basis of interim 
analyses of protracted Phase III trials (Richey et al., 2009). Moreover, a number of adverse 
instances in the drug approval process have raised legitimate concerns by the FDA 
Oncology Drugs Advisory Committee (ODAC), which has essentially created new hurdles, 
for both clinically effective and ineffective agents alike, and has increased the focus on post-
marketing studies (Goozner, 2010, 2011). Therefore, it cannot be considered either expedient 
or logical to undertake a program of clinical development for a new and potentially 
important oncology agent based solely on acceleration of its marketing approval. Rather, the 
heightened and politically-charged regulatory climate encourages the responsible sponsor to 
undertake a robust and long-term program of clinical development, which (i) strengthens 
and improves clinical validation of safety and efficacy, (ii) mitigates the risk that is inherent 
in the conduct of a single clinical trial, (iii) broadens clinical utility (and potential market 
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share) by expanding clinical indications, and (iv) serves to inspire confidence and lasting 
support from regulatory bodies in the fullness of time. 
Commensurate with the fundamental principles of basic science—the step-wise 
demonstrations of physiological tumor-targeting, predictable mechanisms-of-action, 
pharmacological safety, and single-agent anti-tumor activity, including dose-dependent 
survival benefits—is the strident recommendation of the primary inventors that the high-
value biotechnology platform embodied in Rexin-G merits the implementation of a 
comprehensive, progressive, and diversified program of clinical development:  a program of 
clinical development that not only meets but far exceeds the minimal requisites for federal 
regulatory approval. After all, the cancer genetics, the molecular biotechnologies, the 
functional genomics, and the medicinal nanotechnologies embodied within Rexin-G 
represent a nano-architectural triumph of modern medicine. It is within the most stringent 
guidelines and guidance of the U.S. FDA that Phase II and Phase III pivotal studies of Rexin-
G are currently being designed: as first-line therapy in combination with anti-metabolites, as 
stand-alone therapy for second-line indications, and as neoadjuvant/adjuvant therapy in 
combination with surgical procedures.  
With the clinical validation of the tumor-targeted gene delivery platform accomplished, and 
the biopharmaceutical evaluation of Rexin-G as a Phase 3 (i.e., commercial) product 
achieved, the end of one particular Product Development Stage (that of Rexin-G) signals the 
beginning of the next (introducing Reximmune-C). In light of the potential “pipeline” of 
pathotropically targeted anti-cancer agents, it was first reasoned, and then proven in 
preclinical studies, that the same bio-technological platform developed for the targeted 
delivery of the cytocidal designer gene could just as readily deliver an immune-stimulating 
cytokine gene directly to the same cancerous lesions, which would provide a highly-
localized and personalized form of cancer vaccination (Gordon et al., 2007, 2008; Zolnik et 
al., 2010). This two-tier complementary approach—termed the GeneVieve (Genes for Life) 
Protocol—aimed at both tumor eradication and cancer vaccination, was evaluated in a 
limited number of patients who benefited from previous Rexin-G therapy (see Figure 12 
below). The sequential delivery of Rexin-G followed by Reximmune-C, which bears a 
controllable construct of the granulocyte-macrophage colony-stimulating factor (GM-CSF) 
transgene, induced substantial tumor necrosis and recruitment of tumor-infiltrating 
lymphocytes in cancerous lesions without raising the baseline levels of the powerful 
cytokine in the patient’s blood; thereby affirming both general safety and an effective 
Reximmune-C dose range (Cornelio et al., 2010). In the subsequent follow-up of the first 9 
patients receiving the tumor-targeted cancer vaccination in a Phase I/II study of the 
GeneVieve Protocol, a large percentage (> 70%) of these otherwise poor prognosis patients 
exhibited an overall survival beyond one year (Ignacio et al., 2010). By meeting both primary 
and secondary study endpoints—defining a safe and effective dose range—these findings 
indicate that this strategic combination of two pathotropic medicines (Rexin-G plus 
Reximmune-C) is safe and well-tolerated, and may help control tumor growth and prolong 
survival, thus advancing the protocol and the molecular biotechnologies of personalized 
cancer vaccination as a feasible and promising approach. 
Fig. 12 legend: Rationale: “Pathotropic” targeting of therapeutic gene delivery enables 
personalized cancer vaccinations in situ by means of simple intravenous infusions. Rexin-G 
and Reximmune-C are tumor-targeted retrovectors bearing a cytocidal cyclin G1 ‘knockout’ 
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Fig. 12. Bone scans of a patient with metastatic breast cancer obtained at intervals following 
treatment with Rexin-G followed by a two-tier cancer vaccination with Rexin-G plus 
Reximmune-C (The GeneVieve Protocol).  
construct and a controllable GM-CSF expression construct, respectively. The working 
hypothesis for this bipartite tumor-targeted cancer vaccination strategy is that the 
personalized vaccination of a patient against his/her own specific cancer type can be 
achieved by combining (1) a targeted vector bearing a tumoricidal payload, i.e. Rexin-G 
with (2) a targeted vector bearing a potent immuno-stimulatory gene, i.e. Reximmune-C. 
First, Rexin-G is administered to control tumor growth and to expose neoantigens within 
the tumor microenvironment, followed by defined pulses of Reximmune-C, which recruits 
the patient’s immune cells into the lesions, thereby prompting immunologic activation, 
recognition of tumor neoantigens, and induction of an antitumor immunity. Baseline (A); 
post Rexin-G (B); post Rexin-G plus Reximmune C (C). 
12. Looking back and then forward – reflections on proper values and 
valuations 
Looking back over the past decade of scientific and medical achievement in the emerging 
field of targeted genetic medicine, the term decennium mirabilis seems all the more 
appropriate. The technological challenges that once stymied and precluded therapeutic gene 
delivery in vivo have all been overcome. The triad of forbidding challenges of undeveloped 
biotechnology, institutional incredulity, and scientific skepticism have been confronted and 
allayed by a significant amount of scientific and clinical data that heralded the advent of 
pathotropic targeting as an enabling biotechnological platform with a series of sound 
conclusions: (i) it is no longer impossible to reach the fabric of the nature of malignant 
disease itself (i.e., collagen patefacio, from Gordon and Hall, 2009); (ii) it is no longer 
impossible to deliver a sufficient number of therapeutic genes to the appropriate site and get 
them to stay there long enough to impact and reverse the course of metastatic disease 
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(Gordon and Hall, 2010; Hall et al., 2010); (iii) it is no longer appropriate to deny the 
mathematical potentiality of a targeted genetic medicine, in light of the quantitative 
demonstrations of single agent dose-dependent anti-tumor activity, along with the recent 
advances in biopharmaceutical vector production that have raised the potency of the 
clinical-grade vectors more than two orders of magnitude (Gordon and Hall, 2009). Indeed, 
as the development and validation of the world’s first (Waehler et al., 2007; Gordon and 
Hall, 2010), but no longer only (see Reximmune-C; Gordon et al., 2007, 2008), tumor-
targeted genetic medicine is recognized, the promise and potential of the platform have 
begun to percolate into the general medical literature, impacting the practice of clinical 
oncology (Hughes, 2009), medical imaging (Bjojani et al, 2010), medicinal nanotechnology 
(Peach et al., 2009), and gene therapy (Sverdlov, 2009), as well as the discussions of bedside 
bioethics (Toh, 2011) and the practical applications of tumor immunology (Zolnik et al., 
2010).  
Looking forward into the future, it is only a matter of time (see Gordon and Hall, 2009) when 
the progression of metastatic disease is no longer considered to be intractable, and the poor 
prognosis of chemotherapy-resistant cancer is summarily improved. It is also only a matter 
of time, when the potentially “disruptive” biotechnology is eventually viewed as enabling 
platform for further research and development, and the potential of the resulting “pipeline” 
becomes a value-added resource for the biopharmaceutical industry. As the Development 
Stage of this leading genetic medicine comes to a close, and the resources of the academic 
institutions and the idealistic enterprises that initially supported its advancement are 
expended in the process of serving such unmet medical needs, it would be expected that the 
pioneering inventors and the visionary business builders are eventually replaced by 
professional financial institutions and pharmaceutical conglomerates that are capable of 
supporting vast expenditures required for the progressive, diversified programs of late-
stage clinical studies that will expand the clinical applications, optimize the protocols for a 
multitude of new treatment combinations, and ultimately extend the reach of 
pathotropically-targeted gene delivery into the evolving praxis of modern and post-modern 
medicine. One can only hope that the abiding values of inspiration and compassion that 
once fueled the hearts and minds of the physicians and scientists who carried this platform 
thus far for the benefit of the cancer patient, will not be lost entirely in the valuations to 
come.           
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